Oridion Systems Ltd : Oridion Preliminary Financial Results for 2011

Oridion announced today additional preliminary unaudited financial results for fiscal year 2011. Revenues came to approximately USD 64.5 million, slightly higher than the first indication that the Company published on January 10, 2012. Revenue growth in 2011 was approximately 19.0% over the previous year period.
The operating income results include a reserve of approximately USD 1 million for inventory produced by a consumables subcontractor in Israel whose supply relationship was terminated by Oridion in the
4th quarter as a consequence of the FDA-related issues previously reported in October and November of last year. The results also include a one-time USD 0.5 million increase in transport costs of consumables during the 4th quarter, primarily in emergency air transport rather than the normal shipping by sea, which is directly related to the FDA issues as well.
These one-time cost items will be charged to the income statement for fiscal year 2011. Oridion's unaudited operating income for 2011 will be at approximately USD 6.7 million, representing operating margin of 10.4%. Excluding these non-recurring cost items, operating income would have reached approximately USD 8.2 million or 12.7% of operating margin.
Oridion will publish further details of its Financial Statements and the 2011 Annual Report on February
27, 2012.

Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations
e-mail investor@oridion.com website http://www.oridion.com phone +972 2 589 9159
address Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

February 27, 2012 Results 4th Quarter / Fiscal Year 2011

Oridion Systems Ltd. (www.oridion.com) is a global medical device company specializing in patient
safety monitoring. The Company operates through wholly owned subsidiaries in Israel and the United
States.
Oridion develops proprietary medical devices and patient interfaces, based on its patented
Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon
dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward- looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology; resolution of the final nature of the recall; future actions of the FDA with respect to the Company's implementation of the recall; future actions of the FDA or any other regulatory body or government authority that could delay, limit or suspend product development, manufacturing or sale or result in seizures, injunctions, monetary sanctions or criminal or civil liabilities; product quality or patient safety issues.

Furthermore, this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company's shares issued have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant Securities Laws of any state of the United States. The Company's shares may not be offered, sold or delivered, directly or indirectly, to, or for, the account of any US person (as defined in regulation S under the Securities Act) in or into the United States, or by use of the US mail, or by any means or instrumentality of United States interstate commerce, absent registration, or an exemption from registration under the Securities Act.

2

distribué par	Ce noodl a été diffusé par Oridion Systems Ltd. et initialement mise en ligne sur le site http://www.oridion.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-26 07:25:54 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.
	Documents associés
	Oridion Preliminary Financial Results for 2011